Version October 2020
Overall, the Global Parkinson’s Genetics Program (GP2) aims to have a “no surprises” policy where analyses, projects and manuscripts are coordinated and communicated in an open and transparent manner. GP2 wants the data to be used as widely and openly as possible. For consortium led manuscripts (e.g. a large GWAS), all contributing researchers will be included as authors and the manuscript will be shared within the full GP2 network two weeks prior to submission. For GP2 members that do sub-analyses using GP2 data (e.g. gene/locus specific study), only actively contributing researchers will be included as named authors in the author list, however the GP2 banner will be included in the author list and thus all GP2 researchers will be supplemental authors, searchable on PubMed. The manuscript will be shared within the full GP2 network two weeks prior to submission. For external non-GP2 led manuscripts (e.g. external user analysis or summary statistics sub-analysis), GP2 will be acknowledged and the manuscript will be shared within the full GP2 network two weeks prior to submission. Preprint uploads (e.g. bioRxiv), open access publications and code sharing is mandatory for GP2 led manuscripts and highly encouraged for external manuscripts using GP2 data.
The Global Parkinson’s Genetics Program (GP2) is an international effort aimed at generating significant insight into the genetic basis of Parkinson’s disease (PD) and democratizing access to results and data. GP2 is funded by the Aligning Science Across Parkinson’s initiative (ASAP, https://gp2.org/) and it is part of this program’s strategic objectives to support collaboration, generate resources, and democratize data. Dissemination of GP2 data is a major goal of the GP2 project and ASAP encourages the broad, rapid, and open publication of results.
The aim of this policy is to ensure that:
- GP2 data and results are disseminated fully, accurately, and expeditiously
- GP2 study members are recognized for their effort in study design, acquisition, and analysis of data and collection of biospecimens
- GP2 publications may be tracked to develop a complete record of the findings resulting from GP2 efforts
- Results from analysis of GP2 data are open and available to the public free of charge whenever possible
Publications authored by the GP2 Steering Committee, Working Groups, and any other recipients of GP2 funding will follow the ASAP and The Michael J. Fox Foundation (MJFF) Open Access Policies posted here and www.michaeljfox.org/openaccesspolicy, respectively. To promote open sharing of results, external users of GP2 data who do not receive GP2 funding are strongly encouraged to follow the ASAP and MJFF Open Access Policies as well.
Results and code sharing
Per the ASAP and MJFF Open Access Policies, the GP2 Steering Committee, Working Groups, and any other recipients of GP2 funding will make all results and
code, either curated or generated through analysis of GP2 data, publicly available and easily accessible online through data platforms such as the Accelerating Medicines Partnership: Parkinson’s Disease (AMP PD) platform, https://www.protocols.io/, https://github.com/, and https://www.ebi.ac.uk/gwas/, as early as possible and when feasible. This includes summary statistics, metadata, documentation, and intended computational use cases, as appropriate. For code sharing guidelines see the GP2 Best Practices and Code Standardization Practices to Adopt document for more details. To promote open sharing of results and code, external users of GP2 data who do not receive GP2 funding are strongly encouraged to share their results and code on publicly available online data platforms as well.
All manuscripts, preprints, and abstracts/posters using GP2 data must be sent to GP2 for administrative review prior to submission to any journal, public database, or conference. GP2 will respond to all submissions within two weeks. To submit a manuscript or abstract/poster to the GP2 Steering Committee, email [email protected].
All manuscripts, preprints, and abstracts/posters that result from use of GP2 data must acknowledge ASAP and GP2 using the following language:
“Data used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Against Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.”
Researchers may use GP2 data for any projects/analyses of interest that are in compliance with the GP2 data use agreement. There will be three types of GP2 publications:
Consortium-led, GP2-focused papers
1) On papers authored by the GP2 Steering Committee or Working Groups and primarily based on the GP2 collaborative data set, all GP2 members will be co-authors and the consortium name (Global Parkinson’s Genetics Program (GP2) Consortium) will be placed after the senior authors (depending on journal guidelines). All named authors should see, comment, and agree to the submission of the paper prior to submission. Authors can actively opt out from inclusion in the authorship list and any co-authors who do not respond within two weeks to requests to comment on a manuscript or to provide information requested by journals can be removed from the author line to be placed in the Acknowledgement section.
Papers incorporating GP2 data in a secondary fashion
2) For analyses where the individual genotype data from the GP2 database are used in a secondary manner (e.g. to replicate results from non-consortium data or gene/locus focused manuscript), members of the primary analysis and writing groups are named authors. All others are listed under the consortium name, which is included in the authorship list between first and last authors. The authors listed under the consortium name will appear and be searchable in PubMed once fully processed by PubMed. All named and footnoted authors should see, comment and agree to the submission of the paper prior to submission. Authors can actively opt out from inclusion in the authorship list, and any co-authors who do not respond within two weeks to requests to comment on a manuscript.
3) The consortium name may not appear on the author line for publications authored by non-consortium members. For these publications, the consortium members will also not be listed in PubMed.
Per the Acknowledgement section above, all publications using GP2 data must include an acknowledgement of ASAP and GP2.
It is expected that the aforementioned policies will cover the majority of users of GP2 data. GP2 anticipates that investigators will follow these guidelines in good faith and that most analyses will be of high quality. However, GP2 also anticipates the possibility of some unusual circumstances.
Egregiously Poor Manuscripts
If review by the GP2 Steering Committee of a proposed manuscript reveals that it is egregiously poor in terms of language, scientific question, analytical methods, writing, or clarity, the GP2 Steering Committee can recommend to the authors that it not be submitted without significant revision. If the authors choose to submit the manuscript anyway, the GP2 Steering Committee will have three options: 1) request that the group authorship credit be withheld; 2) request that the authors publish a statement to the effect that, while GP2 data were used, the GP2 study did not find the manuscript of sufficient merit to warrant submission for publication; 3) revocation of privileges to use GP2 data in the future.
Failure to Follow GP2 Data Use Agreement
If users inadvertently violate the GP2 data use agreement, it is likely that they will self-correct as infractions are discovered. If users willfully violate the agreements, the sole sanction available to GP2 will be to revoke access to the GP2 data.
Fraudulent Use of Data
Open access using only online registration raises the possibility that individuals could obtain access to data under false pretenses. Should the GP2 Steering Committee discover an attempt to publish using GP2 data obtained fraudulently, the user will be sanctioned through communication from the GP2 Steering Committee to the researcher or their supervisors, persons/committees responsible for oversight, and/or governing bodies. As soon as the GP2 Steering Committee becomes aware of any breach of the data use agreement, immediate steps will be taken to cure the breach or end the violation. This may include discontinuing the user’s data access and/or reporting the violation to any relevant individual/organization.
The Michael J. Fox Foundation, ASAP, and the GP2 Steering Committee maintain the right to modify terms of this agreement, and may do so by posting notice of such modifications on this page. Any modification made is effective immediately upon posting the modification (unless otherwise stated). You should visit this page periodically to review the current use agreement terms.